Why market sequencing matters
Market entry is not a geography question — it is an evidence question. Each jurisdiction's regulatory route, reimbursement structure and clinical ecosystem determines what proof you need, in what order, at what cost. A company that launches where its existing evidence travels furthest preserves runway; one that chases the largest market first often pays for evidence twice.
Sequencing also compounds. A first authorization becomes reference evidence elsewhere, early clinical sites become long-term partners, and early reimbursement wins set pricing precedent.
The dimensions that should drive the decision
- Regulatory pathway friction — classification, review timelines, and whether your existing evidence is accepted.
- Reimbursement and payment — coding, coverage and payment pathways for your device category.
- Market size and disease burden — addressable patient population and procedure volumes.
- Clinical ecosystem — trial sites, key opinion leaders and research infrastructure.
- Competitive intensity — who already holds the category and how entrenched they are.
- Pricing environment — what payers actually pay for comparable technologies.
- Policy momentum — incentives, fast-track programs and digital-health initiatives.
- Manufacturing and supply chain — proximity, cost and infrastructure shifts.
- Data and localization rules — privacy regimes that constrain software and cloud deployment.
- Language and commercial overhead — labeling, support and distribution complexity.
Weighting these dimensions explicitly — rather than debating markets anecdotally — is what separates a defensible launch plan from a slide deck. MedTechCompass scores curated markets across exactly these dimensions, anchored to admin-curated baselines with device-specific adjustments.
How the core markets compare
| Market | Regulatory character | Entry consideration |
|---|---|---|
| United States | FDA 510(k)/De Novo/PMA; largest single market | Highest commercial value; evidence generated here travels well globally. |
| European Union | EU MDR with notified-body capacity constraints | CE marking grants 27-country access but timelines have stretched under MDR. |
| United Kingdom | UKCA/CE recognition transition post-Brexit | Often paired with EU plans; standalone UK route still evolving. |
| Japan | PMDA review; strong reimbursement discipline | High-value market with local partner and language requirements. |
| China | NMPA; local testing and data expectations | Large demand but significant localization and regulatory overhead. |
| Brazil | ANVISA; INMETRO certification for electrical devices | Latin America's anchor market with meaningful administrative burden. |
| Australia | TGA recognizes many overseas authorizations | Frequent early-launch choice; efficient when you hold FDA or CE evidence. |
| UAE | Regional hub with growing health investment | Fast-growing Gulf gateway; smaller absolute volumes. |
| India | CDSCO; price-sensitive, high-volume | Scale opportunity with strong price pressure and evolving rules. |
| Canada | Health Canada; MDSAP-aligned | Common second market after the US with moderate friction. |
A practical 90-day planning approach
- Days 1–15: fix your intended use and classification hypotheses for each candidate market.
- Days 15–40: map the regulatory route and evidence gap per market — what you have versus what each route demands.
- Days 40–65: score candidate markets across the dimensions above with explicit weights tied to your device profile.
- Days 65–80: pressure-test the top two markets on reimbursement reality and clinical-site access.
- Days 80–90: commit to a sequencing decision with decision gates — the evidence and commercial milestones that trigger the next market.
Common failure modes
- Choosing by market size alone and discovering the evidence bill exceeds the budget.
- Assuming FDA clearance implies fast EU entry — MDR's notified-body bottleneck surprises many teams.
- Ignoring reimbursement until after clearance, then finding no code or coverage exists.
- Treating market selection as a one-time decision instead of a gated sequence.
Frequently asked questions
Should I always launch in the US first?
Not always. The US offers the largest commercial prize and globally portable evidence, but capital-constrained teams sometimes start in markets that accept existing evidence faster, then use early revenue and data to fund the US program.
How many markets should I plan for at once?
Plan the sequence, execute one or two at a time. A gated plan across three to five markets with explicit trigger milestones beats parallel filings that dilute both budget and management attention.
Where does reimbursement fit in the decision?
Early. In most developed markets, clearance without coding, coverage and payment is a Pyrrhic victory. Treat reimbursement feasibility as a first-class dimension in your scoring, not a post-clearance task.
How does MedTechCompass support this?
The platform scores curated markets across ten dimensions with device-specific, evidence-grounded adjustments, lets you weight the dimensions to match your strategy, and exports a single-market report with decision gates and a 90-day entry plan.
Go deeper with MedTechCompass
Describe your device in plain language and get an AI-assisted triage: likely FDA class, product codes, premarket pathway, EU MDR and UK considerations — plus market attractiveness scoring across curated global markets.
This article is educational content from CAHIR Solutions and is not legal or regulatory advice. Regulatory decisions depend on your specific intended use and claims — confirm them with FDA resources, a qualified consultant, or a pre-submission meeting before filing.